title: Cilostazol attenuates cholestatic liver injury and its complications in common bile duct ligated rats.
abstract: Cilostazol is a phosphodiesterase III inhibitor increases adenosine 3', 5'-cyclic monophosphate (cyclic AMP) level which inhibits hepatic stellate cell activation. Its pharmacological effects include vasodilation, inhibition of vascular smooth muscle cell growth, inhibition of platelet activation and aggregation. The aim of the current study was to determine the effects of early administration of low dose cilostazol on cholestatic liver injury induced by common bile duct ligation (CBDL) in rat. Male Wistar rats (180-200g) were divided into three groups: Group A; simple laparotomy group (sham). Group B; CBDL, Group C; CBDL rats treated with cilostazol (9mg/kg daily for 21 days). Six rats from each group were killed by the end of weeks one and three after surgery, livers and serum were collected for biochemical and histopathological studies. Aspartate aminotransferase, alanine aminotransferase, gama glutamyl transferase, alkaline phosphatase and total bilirubin serum levels decreased in the cilostazol treated rats, when compared with CBDL rats. The hepatic levels of tumor necrosis factor-alpha, transforming growth factor-beta, and platelet derived growth factor-B were significantly lower in cilostazol treated rats than that in CBDL rats. Cilostazol decreased vascular endothelial growth factor level and hemoglobin content in the livers. Cilostazol significantly lowered portal pressure, inhibited ductular proliferation, portal inflammation, hepatic fibrosis and decreased hepatic hydroxyproline contents. Administration of cilostazol in CBDL rats improved hepatic functions, decreased ductular proliferation, ameliorated portal inflammation, lowered portal hypertension and reduced fibrosis. These effects of cilostazol may be useful in the attenuation of liver injury in cholestasis.
authors: Department of Pharmacology, Faculty of Medicine, Ain Shams University, Abbasia, Cairo, Egypt. Electronic address: halapharmacology@yahoo.com.
authors: Hala S
authors: HS
authors: Abdel Kawy
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D002779:Cholestasis / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000077407:Cilostazol; D003135:Common Bile Duct / Q000601:surgery*; D004305:Dose-Response Relationship, Drug; D006454:Hemoglobins / Q000378:metabolism; D008026:Ligation / Q000009:adverse effects*; D008099:Liver / Q000187:drug effects* / Q000293:injuries* / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D009389:Neovascularization, Pathologic; D017082:Portal Pressure / Q000187:drug effects; D011392:Proline / Q000378:metabolism; D020574:Proto-Oncogene Proteins c-sis / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000199:Actins; D006454:Hemoglobins; D020574:Proto-Oncogene Proteins c-sis; D013777:Tetrazoles; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D011392:Proline; D000077407:Cilostazol
keywords: Cilostazol; Common bile duct ligated; Hepatic fibrosis; Hepatic stellate cells